Sign in Subscribe
Pharmaceutical industry

Aurora A Kinase Inhibition Shows Promise in Cancer Therapy

Strategic Insights

— 1 min read

Aurora A kinase is an essential therapeutic target in cancer treatment, according to a study published in Cancer Research. Researchers from Millennium Pharmaceuticals, Inc. evaluated the effectiveness of MLN8054, a small-molecule inhibitor of Aurora A kinase, in patients with advanced solid tumors. The study revealed promising results, with several patients showing marked increases in the skin mitotic index and decreases in the percentage of mitotic cells with aligned chromosomes and bipolar spindles after dosing.

Key Takeaways:

  • The study evaluated the efficacy of MLN8054, a small-molecule inhibitor of Aurora A kinase, in patients with advanced solid tumors.
  • Patients received MLN8054 orally for 7 consecutive days in escalating dose cohorts, with skin and tumor biopsies obtained before and after dosing.
  • Several patients in the highest dose cohorts showed marked increases in the skin mitotic index after dosing, indicating Aurora A inhibition.
  • The study assessed new biomarkers of Aurora A inhibition, including mitotic cell chromosome alignment and spindle bipolarity, which were found to be effective in evaluating the drug's efficacy.
  • A biologically active dose range of MLN8054 was identified, with an exposure-effect relationship for mitotic cells with defects in chromosome alignment and spindle bipolarity.
  • The outcomes of pharmacodynamic assays from skin and tumor biopsies were concordant in several patients, providing evidence for Aurora A inhibition by MLN8054.

Statistics:

  • 7 consecutive days: duration of MLN8054 treatment in the study
  • 11.4%: increase in skin mitotic index in patients receiving the highest dose of MLN8054
  • 75.6%: decrease in percentage of mitotic cells with aligned chromosomes and bipolar spindles in patients receiving the highest dose of MLN8054
  • 2: number of phase I studies conducted on MLN8054, a small-molecule inhibitor of Aurora A kinase

Sources:

  • Chakravarty, A., et al. (2011). Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Research, 71(3), 675-85.
  • Small Molecule Inhibitors. (n.d.). Retrieved from [Source not available]

Read more